To address the possibility that PCSK9 is indirectly modulating AD pathophysiology, we measured AD biomarkers in the CSF of pre-symptomatic “at-risk” individuals and contrasted each marker to PCSK9 levels. This evidence concerns the gene PCSK9 and Alzheimer disease.